(MedPage Today) — AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, successfully lowered blood pressure (BP) in people with uncontrolled or treatment-resistant hypertension in the BaxHTN trial.
Bedtime antihypertensives…
Source link : https://www.medpagetoday.com/cardiology/prevention/116507
Author :
Publish date : 2025-07-15 18:41:00
Copyright for syndicated content belongs to the linked Source.
